Author: seelostherapeutics

Dr. Raj Mehra Interview with CheckRare – Rare and Genetic Disease Network on Sanfilippo Syndrome

CheckRare interviewed Raj Mehra, PhD of Seelos Therapeutics on Sanfilippo Syndrome. Please follow this link for the archive of this interview: https://checkrare.com/sanfilippo-syndrome-2/

Dr. Raj Mehra Interview with Nicole Petallides of TD Ameritrade Network’s “The Watchlist”

Live from the Nasdaq market site, Nicole Petallides of TD Ameritrade Network’s “The Watchlist” interviewed Raj Mehra, PhD on Seelos Therapeutics’ pipeline developments and corporate highlights on March 25, 2019. Please follow this link for the archive of this interview: https://tdameritradenetwork.com/video/rB4AoWmoG5SBabX3gpQB8Q

Archive Webcast of Seelos Presentation at Cowen’s 39th Annual Health Care Conference

by Anthony Marciano On the morning of March 13, 2019 Dr. Raj Mehra presented at Cowen’s 39th Annual Health Care Conference in Boston, MA.  The webcast link for this archived presentation is located at: http://wsw.com/webcast/cowen52/seel/

Dr. Raj Mehra Interview with Proactive Investors

by Anthony Marciano On the morning of March 8, 2019 Dr. Raj Mehra was interviewed by Proactive Investors. Among the notable items in this video interview, Dr. Mehra shared how the company has acquired an exclusive license to the rights to a potential Parkinson’s disease therapy created by researchers at the University of California, Los…
Read more

Our Acquisition of a Disease-Modifying Parkinson’s Disease Therapy

by Anthony Marciano On March 07, 2019, Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced it acquired an exclusive license to intellectual property owned by The Regents of the University of California (The UC Regents) pertaining to a technology that was created by researchers at the University of California, Los Angeles (UCLA). Such technology relates to a…
Read more

Our Acquisition of Trehalose and Collaboration with Team Sanfilippo Foundation (TFS)

Our Acquisition of Trehalose and Collaboration with Team Sanfilippo Foundation (TFS) by Anthony Marciano On February 19, 2019, Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced a definitive agreement with Bioblast Pharma Ltd., (Nasdaq: ORPN), whereby Seelos acquired all development and commercial rights to Bioblast’s proprietary trehalose 90 mg/mL IV (Trehalose) solution as well as the existing…
Read more

Addressing Suicidality

Addressing Suicidality by Samantha Miernicki, PharmD Every 12 minutes, approximately one death occurs due to suicide, according to the most recent data published in 2016 from the Centers of Disease Control and Prevention. In 2016, 9.8 million American adults seriously thought about suicide, 2.8 million created a plan to commit suicide, and 1.3 million attempted…
Read more

Welcome to Thinking Seelos

Welcome to Thinking Seelos by Raj Mehra, PhD Raise the curtain for our new Thinking Seelos blog Welcome to our new corporate website and our Thinking Seelos blog. Here’s where you’ll find the latest and greatest news on everything about Seelos Therapeutics  – from newsworthy updates to interviews with our Seelos colleagues. Along the way,…
Read more